BSX|Analyst Targets
BSX|Company Info
BSX|Insider Trading
BSX|Fundamentals
BSX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.76 | - | - |
| Q2'26 | $0.83 | $0.86 | +3.9% |
| Q1'26 | $0.79 | $0.80 | +1.6% |
| Q4'25 | $0.79 | $0.80 | +1.6% |
| Q3'25 | $0.71 | $0.75 | +5.1% |
| Q2'25 | $0.73 | $0.75 | +3.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $5.2B | - | - |
| Q2'26 | $5.4B | $5.4B | +0.5% |
| Q1'26 | $5.2B | $5.2B | +0.6% |
| Q4'25 | $5.3B | $5.3B | -0.9% |
| Q3'25 | - | $5.1B | - |
| Q2'25 | - | $5.1B | - |
BSX|Monthly Returns
Market Data
BSX Stock Snapshot
- Market cap
- 62.07B
- P/E ratio
- 16.9
- Day range
- $41.81 – $42.52
- News sentiment
- 49/100 · Neutral
- Analyst target
- $60.79 (+43.6%)
- Consensus
- Buy · 40 analysts
BSX is on the weaker side of its setup, with little confirmation for a reversal yet. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Reverse DCF
What growth is priced into BSX?
At today's price, Boston Scientific Corporation needs to grow free cash flow about 4.4% a year for the next 10 years to justify its valuation at a 8.11% cost of capital. Over its actual history it has compounded free cash flow at 10.7% a year, so the market is asking for 6.3 percentage points below its own delivered rate. On that basis BSX looks priced below what its own growth record supports.
- Implied FCF growth
- 4.4%
- Historical FCF CAGR
- 10.7%
- Growth gap
- -6.3 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 8.11%
- Beta
- 0.77
Behaviour On Record
What BSX's own history says about today's numbers
- Realized volatility (21d)
- 32.7% 81st pct
- Below its peak
- -61.0%
- vs 200-day average
- -31.4%
- Up days (1y)
- 46%
Boston Scientific Corporation is currently running 32.7% annualised volatility over the last 21 sessions. Measured against BSX's own 13 years of daily returns rather than a market-wide average, that is the 81st percentile — elevated for this stock, against a typical reading of 23.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
BSX is trading -61.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.7%, and the deepest was -42.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -31.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 3rd percentile — a narrower gap than it typically runs. Over the past year BSX closed higher on 46% of sessions, and it is currently 3 sessions into a falling streak.
On October specifically: over 13 years of records, BSX finished the month higher 6 of 13 times, with a median return of -0.6% and an average of +0.4%. Its strongest month historically has been January at +5.5% on average, its weakest September at -2.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: BSX has opened more than 2% away from the prior close in 123 of 3,267 sessions (3.8% of the time), with the largest gaps running +9.8% and -9.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, BSX moved an average of 1.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.5% and a largest of +2.1%.
All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against BSX's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of BSX's sector?
Boston Scientific Corporation sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Medical Devices industry group, BSX ranks 3rd of 15 tracked industries, lagging.
- Sector rank
- #3 of 12
- Sector state
- Weakening
- Sector rotation score
- 82
- Industry rank
- #3 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on BSX?
Wells Fargo most recently reiterated its rating on Boston Scientific Corporation to Equal-Weight on Sep 24, 2026 with a price target of $48 (from $50). Over the last 90 days, coverage has run 0 upgrades against 2 downgrades, a net bearish lean.
- Latest action
- Wells Fargo — Equal-Weight
- 90-day upgrades
- 0
- 90-day downgrades
- 2
- Net rating momentum
- -2
BSX Competitive Positioning
- BSXyou're hereBoston Scientific Corporation$62.1B+0.36%
- ABTAbbott Laboratories$173.1B+0.55%
- MDTMedtronic plc$112.3B-0.46%
- SYKStryker Corporation$107.6B+0.31%
- DXCMDexCom, Inc.$32.3B+1.95%
- ZBHZimmer Biomet Holdings, Inc.$17.5B-0.10%
Held by These ETFs
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 139,685,997 | 9.49% | $13.32B | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 129,680,916 | 8.81% | $5.53B | 2026-08-07 |
| FMR LLC (Fidelity) | ▼ Sell | 45,702,845 | 3.11% | $1.95B | 2026-08-13 |
| Geode Capital Management, LLC | ▲ Buy | 33,440,102 | 2.27% | $1.42B | 2026-08-12 |
| JPMorgan Chase & Co | ▼ Sell | 28,133,038 | 1.91% | $1.22B | 2026-08-12 |
| D. E. Shaw & Co., Inc. | ▲ Buy | 27,267,209 | 1.85% | $1.16B | 2026-08-14 |
| Janus Henderson Group plc | • Hold | 16,497,366 | 1.12% | $1.04B | 2026-05-18 |
| Norges Bank | ▼ Sell | 21,170,029 | 1.44% | $903.54M | 2026-08-12 |
| Two Sigma Investments, LP | ▲ Buy | 19,420,323 | 1.32% | $828.86M | 2026-08-14 |
| Goldman Sachs Group Inc | ▼ Sell | 19,207,742 | 1.31% | $819.79M | 2026-08-14 |
| Morgan Stanley | ▼ Sell | 18,947,147 | 1.29% | $808.66M | 2026-08-13 |
| Capital World Investors | ▲ Buy | 16,812,257 | 1.14% | $717.60M | 2026-08-12 |
| Wellington Management Group LLP | ▼ Sell | 15,301,828 | 1.04% | $653.08M | 2026-08-14 |
| Capital Research Global Investors | ▲ Buy | 14,180,571 | 0.96% | $605.26M | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 13,800,748 | 0.94% | $589.02M | 2026-08-14 |
| Bank of America Corp | ▼ Sell | 13,027,783 | 0.89% | $556.03M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 12,964,638 | 0.88% | $553.33M | 2026-08-13 |
| Egerton Capital (UK) LLP | ▲ Buy | 5,385,084 | 0.37% | $513.47M | 2026-02-11 |
| Farallon Capital Management LLC | ▲ Buy | 10,521,184 | 0.72% | $449.04M | 2026-08-14 |
| Citadel Advisors LLC | • Hold | 10,155,348 | 0.69% | $433.43M | 2026-09-02 |
| AQR Capital Management LLC | ▲ Buy | 9,681,750 | 0.66% | $413.22M | 2026-08-14 |
| Susquehanna International Group, LLP | ▼ Sell | 6,554,450 | 0.45% | $279.74M | 2026-08-14 |
| Maverick Capital Ltd | ▲ Buy | 5,937,553 | 0.40% | $253.41M | 2026-08-14 |
| Viking Global Investors LP | ▼ Sell | 2,509,808 | 0.17% | $239.31M | 2026-02-17 |
| Millennium Management LLC | ▲ Buy | 5,938,867 | 0.40% | $232.13M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Kevin Hern | House | OK01 | ▼ Sell | $50K - $100K | 2026-09-09 | 2026-09-25 |
| Kevin Hern | House | OK01 | ▼ Sell | $50K - $100K | 2026-09-04 | 2026-09-25 |
| Kevin Hern | House | OK01 | ▼ Sell | $1K - $15K | 2026-09-03 | 2026-09-25 |
| Kevin Hern | House | OK01 | ▼ Sell | $15K - $50K | 2026-08-31 | 2026-09-25 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-08-18 | 2026-09-10 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-06-05 | 2026-07-02 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-06-05 | 2026-07-02 |
| John Boozman | Senate | AR | ▼ Sell | $1K - $15K | 2026-06-04 | 2026-07-13 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-05-29 | 2026-06-08 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-05-19 | 2026-06-08 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-05-11 | 2026-06-08 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-02-10 | 2026-03-09 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-01-30 | 2026-02-13 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-12-24 | 2026-01-12 |
| John Boozman | Senate | AR | ▼ Sell | $1K - $15K | 2025-12-17 | 2026-01-13 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-31 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Kevin Hern | House | OK01 | ▼ Sell | $15K - $50K | 2025-10-28 | 2025-11-16 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-10-17 | 2025-11-18 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-08-04 | 2025-09-12 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-07-31 | 2025-08-14 |